linezolid (Zyvox) + vancomycin
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Methicillin Resistant Staphylococcus Aureus (MRSA)
Conditions
Methicillin Resistant Staphylococcus Aureus (MRSA)
Trial Timeline
Oct 1, 2004 → Mar 1, 2010
NCT ID
NCT00084266About linezolid (Zyvox) + vancomycin
linezolid (Zyvox) + vancomycin is a approved stage product being developed by Pfizer for Methicillin Resistant Staphylococcus Aureus (MRSA). The current trial status is completed. This product is registered under clinical trial identifier NCT00084266. Target conditions include Methicillin Resistant Staphylococcus Aureus (MRSA).
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01819935 | Pre-clinical | Completed |
| NCT00084266 | Approved | Completed |
Competing Products
3 competing products in Methicillin Resistant Staphylococcus Aureus (MRSA)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Dalbavancin + Vancomycin + Oxacillin + Flucloxacillin + Cefadroxil + Clindamycin | AbbVie | Phase 3 | 77 |
| Imipenem/cilastatin | Pfizer | Approved | 84 |
| Linezolid + Vancomycin | Pfizer | Pre-clinical | 22 |